|Title:||17.beta.-N-monosubstituted carbamoyl-4-aza-5.alpha.-androst-1-en-3-ones which are active as testosterone 5.alpha.-reductase inhibitors|
|Abstract:||This invention is for the compound 17.beta.-(N-t-butylcarbamoyl)-4-aza-5.alpha.-androst-1-en-3-one, pharmaceutical compositions containing the compound, methods of inhibiting testosterone 5.alpha.-reductase with the compound and methods of treating hyperandrogenic conditions with the compound, particularly benign prostatic hypertrophy.|
|Inventor(s):||Rasmusson; Gary H. (Watchung, NJ), Reynolds; Glenn F. (Westfield, NJ)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.